Arcutis Biotherapeutics, Inc.

Total Valuation

Arcutis Biotherapeutics, Inc. carries a market capitalization of 3.17B, placing it among publicly traded companies globally. Its enterprise value stands at 2.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Arcutis Biotherapeutics, Inc. currently has 125.04M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 7.26, and the price-to-book ratio stands at -2.62.

Enterprise Valuation

On an enterprise value basis, Arcutis Biotherapeutics, Inc. trades at an EV/EBITDA multiple of 532.26 and an EV/FCF ratio of 58.06. The EV/Sales ratio of 7.00 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 904.99 provides insight into valuation relative to core operating earnings.

Financial Position

Arcutis Biotherapeutics, Inc. maintains a current ratio of 2.68, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 60.47, indicating elevated leverage, while an interest coverage ratio of 0.41 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Arcutis Biotherapeutics, Inc. has paid 985,000.00 in income taxes, reflecting an effective tax rate of 3.70.

Stock Price Statistics

Arcutis Biotherapeutics, Inc.'s stock has gained approximately 89.46975% over the past 52 weeks. The 50-day moving average sits at 23.15, while the 200-day moving average is 24.42.

Income Statement

Over the trailing twelve months, Arcutis Biotherapeutics, Inc. generated 415.62M in revenue and converted that into -2.38M in net income, yielding earnings per share of -0.02. EBITDA reached 5.46M, while operating income came in at 3.21M.

Balance Sheet

Arcutis Biotherapeutics, Inc. holds 224.00M in cash and equivalents against 114.67M in total debt, resulting in a net debt position of 74.66M. Total book value stands at -1.15B, with working capital of 274.85M providing operational flexibility.

Cash Flow

Arcutis Biotherapeutics, Inc. produced 26.99M in operating cash flow over the past twelve months. After subtracting -78,000.00 in capital expenditures, free cash flow totaled 26.92M - equivalent to 0.21 per share.

Margins

Arcutis Biotherapeutics, Inc. operates with a gross margin of 90.94, reflecting its pricing power and cost economics. The operating margin of 0.77 and net profit margin of -0.57 provide insight into operational efficiency.

Dividends & Yields

Scores

Arcutis Biotherapeutics, Inc. posts an Altman Z-Score of 4.78, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.